Three previous meta-analyses showed that therapy consisting of adjuvant EGFR-TKIs had specific advantage over placebo or adjuvant chemotherapy in terms of DFS for NSCLC patients with EGFR mutations undergoing complete resection, but the overall survival (OS) could not be synthesized because of immature follow-up data. This evidence concerns the gene EGFR and non-small cell lung carcinoma.